RAS blockers may protect patients with T2DM from pneumonia
Findings from the Australian cohort could be useful in the COVID-19 pandemic, researchers suggest
People with type 2 diabetes mellitus (T2DM) who are taking renin-angiotensin system (RAS) blockers may be reducing their risk of hospitalisation for a severe lower respiratory tract infection, Australian researchers say.
The findings, based on data from the Fremantle Diabetes Study, showed that patients on RAS blockers had a 36% reduction in the risk of hospitalisation for influenza or pneumonia compared with others not on the drugs, over a mean follow-up of 6.4 years.
